Actualizado 08/12/2011 17:20
- Comunicado -

Takeda's Edarbi® (azilsartan medoxomil) Receives European Marketing Authorisation for the Treatment of Essential Hyperte

        
        Contacts
        Takeda Pharmaceutical Company Limited
        Corporate Communications Dept.
        +81-3-3278-2037
        Takeda Pharmaceuticals Europe Ltd
        Rob Gallo
        +44-203-116-8874
        robert.gallo@tpeu.co.uk
        Victoria Boswell-Smith
        Virgo HEALTH
        +44-208-939-2458
        Victoria.boswell-smith@virgohealth.com

CONTACT: .

Contenido patrocinado